The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Dr. Mark LaMeir and Dr. Carlo de Asmundis treated the first patient in the HEAL-IST trial evaluating the AtriCure Isolator Synergy clamp for treating drug-refractory patients diagnosed with inappropriate sinus tachycardia (IST) at University Hospital Brussels.

“Symptomatic IST is a serious arrhythmia that dramatically decreases the quality of life in predominantly younger adults, and more specifically, young women,” Dr. LaMeir, Head of Cardiac Surgery at University Hospital Brussels and co-principal investigator in the HEAL-IST trial, said in a news release. “Further, since current antiarrhythmic drug treatment has limited long-term effect, and societal guidelines do not advise sinus node ablation or modulation, this landmark study of sinus node sparing hybrid ablation has the potential to establish a standard of care for these patients.”

Mason, Ohio-based AtriCure’s Isolator Synergy clamp is the first and only surgical ablation device offered with FDA approval for the treatment of AFib and the only device — either catheter or surgical — to be approved for the treatment of persistent and long-standing persistent AFib, according to the company.

The HEAL-IST trial of 142 patients at up to 40 centers in the U.S. and Europe is evaluating a therapy involving a hybrid epicardial and endocardial procedure in which a cardiac surgeon and an electrophysiologist work together to create lesions on the right side of the heart. It has a primary effectiveness endpoint of freedom from IST, with a primary safety endpoint of procedure- or device-related adverse events through 30 days after the surgery is completed.

“We believe that cardiac surgeons and electrophysiologists working together is a safe and highly effective way to treat complex arrhythmias,” AtriCure President and CEO Michael Carrel said. “The HEAL-IST trial is an example of AtriCure’s commitment to, and leadership in improving the lives of patients. The therapy has the potential to significantly expand our addressable markets.”

Filed Under: Cardiovascular, Clinical Trials, Vascular Tagged With: atricure, AtriCure Inc.

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.